Displaying all 2 publications

Abstract:
Sort:
  1. Muzammil K, Khaleel AQ, Merza MS, Kyada A, Ariffin IA, Verma S, et al.
    PMID: 39243880 DOI: 10.1016/j.prostaglandins.2024.106887
    BACKGROUND & AIMS: Taking into account the anti-inflammatory and antioxidant properties of omega-3 fatty acids and the evidence indicating the role of chronic inflammation and oxidative stress in the pathophysiology diabetes, this study aimed to determine the effect of ω-3 fatty acids on oxidative stress and inflammatory markers in Type 2 diabetes mellitus (T2DM) patients.

    METHODS: A systematic search up to July 30, 2023 was completed in Scopus, PubMed, Web of Science, and Embase databases, to identify eligible RCTs. Heterogeneity tests of the selected studies were performed using the I2. Random effects models were assessed and pooled data were determined as standardized mean differences (SMD) with a 95% CI.

    RESULTS: The meta-analysis of 23 trials, involving 1,523 patients, demonstrated a significant decrease in TNF-α (SMD: -1.62, 95% CI: -2.89 to -0.35, P= 0.013) and increase in TAC (SMD: 0.92, 95% CI: 0.33 to 1.52, P = 0.002) following ω-3 fatty acids administration. Meanwhile, supplementation did not have beneficial effects on malondialdehyde, C-reactive protein (CRP), superoxide dismutase (SOD), and interlukin-6 levels. The subgroup analysis revealed a significant decrease in CRP levels and an increase in SOD levels in studies with durations of less than 12 weeks.

    CONCLUSIONS: We found that ω-3 fatty acid intake can significantly decrease TNF-α and increase TAC levels, but this effect was not observed on other markers. Nevertheless, future well-designed with large sample size and long duration RCT studies with precise ω-3 fatty acids dose and ingredients are required to understand better the effects of these compounds and their constituents on oxidative stress and inflammatory markers in T2DM patients.

  2. Saadh MJ, Khaleel AQ, Merza MS, Hassan H, Tomar BS, Singh M, et al.
    PMID: 39260819 DOI: 10.1016/j.prostaglandins.2024.106901
    INTRODUCTION: Dyslipidemia with a considerable progression rate is a primary risk factor for CVDs if left untreated. Dietary interventions have explored the health influences of selenium on lipid profiles in adults, yet the findings remain contentious. This study seeks to determine if selenium supplementation can positively modify the lipid profile (total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), very-low-density lipoprotein cholesterol (VLDL), and high-density lipoprotein cholesterol (HDL-C) in adults.

    METHODS: Using predefined keywords, we searched online databases, including Scopus, PubMed, Web of Science Core Collection, and Google Scholar, for relevant studies published from inception through July 2024. A random-effects meta-analysis was then employed to pool the weighted mean differences (WMD) and 95% CI for outcomes assessed by a minimum of three studies.

    RESULTS: Initially 1,205 studies were obtained out of which 25 RCTs were decided to be included for further analyses. Selenium supplementation reduced VLDL (WMD: -1.53; 95% CI: -2.86, -0.20), but did not change TG (WMD: 1.12; 95% CI: -4.51, 6.74), TC (WMD: -2.25; 95% CI: -6.80, 2.29), LDL-C (WMD: 1.60; 95% CI: -4.26, 7.46), and HDL-C levels (WMD: 0.98; 95% CI: - 0.02, 1.98).

    CONCLUSION: Our study showed significantly reduced VLDL but limited effects were observed in other lipid indexes. More extensive RCTs are required globally to achieve a holistic comprehension of the connection between selenium and lipid profile.

Related Terms
Filters
Contact Us

Please provide feedback to Administrator (afdal@afpm.org.my)

External Links